Drugs / ONCT-808
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05588440 | May 2023 → Sep 2024 | aggressive B-cell non-Hodgkin lymphoma | Oncternal Therapeutics, Inc | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONCT-808 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05588440 ↗ |
| Modality | Cell therapy | “the CAR-T therapy, ONCT-808” NCT05588440 ↗ |
| Route | Intravenous | “administered intravenously” NCT05588440 ↗ |